| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$9.9M | ROE | −131.38% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $4.1M | Trading Days | 1743 |
| 52W High | 11.72 |
| 52W Low | 0.88 |
| % Off High | −91.14% |
| YTD | −67.57% | 1Y | −90.35% |
| 3Y | −99.98% | 5Y | −100.00% |
| Since incept. (ann.) | −77.71% |
| Ann. Volatility (1Y) | 76.38% | Ann. Volatility (3Y) | 116.20% |
| Sharpe (1Y) | −2.70 | Sharpe (3Y) | −1.74 |
| Max Drawdown (1Y) | −91.81% | Max Drawdown (3Y) | −99.98% |
| Beta (3Y, vs SPY) | −0.36 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| CVSI | CV Sciences, Inc. | $4.1M | — |
| SXTP | 60 DEGREES PHARMACEUTICALS, INC. | $4.0M | — |
| JUNS | JUPITER NEUROSCIENCES, INC. | $4.0M | — |
| ELAB | PMGC Holdings Inc. | $4.3M | — |
| ENSC | Ensysce Biosciences, Inc. | $3.7M | — |
| ACUT | Accustem Sciences Inc. | $3.5M | — |
| INBP | INTEGRATED BIOPHARMA INC | $4.7M | 5.0 |
| RNAZ | Transcode Therapeutics, Inc. | $4.8M | — |
| ENVB | Enveric Biosciences, Inc. | $4.9M | — |
| DRMA | Dermata Therapeutics, Inc. | $5.0M | — |
| APVO | Aptevo Therapeutics Inc. |
| $5.2M |
| — |
| GOVX | GeoVax Labs, Inc. | $5.4M | — |
